Featured Post

AI for HFpEF and HFmrEF

Us2.ai HFpEF evaluation compared to gold standard invasive hemodynamic measurement

By Us2.ai / 24 April, 2024 / Comments Off on Us2.ai HFpEF evaluation compared to gold standard invasive hemodynamic measurement

New research using Us2.ai in comparison to gold standard invasive hemodynamic measurement showed that in patients with HFpEF, AI measurements of echo parameters are interchangeable with manual core-lab measures to diagnose increased filling pressures. “Evaluation of left ventricular filling pressures using non-invasive techniques is the holy grail of cardiac imaging in the setting of heart…

Read More
Us2.ai Fda Clearance

Us2.ai receives FDA clearance for Us2.v2, transforming cardiovascular ultrasound analysis

By Us2.ai / 5 April, 2024 / Comments Off on Us2.ai receives FDA clearance for Us2.v2, transforming cardiovascular ultrasound analysis

Singapore – April 5, 2024 — Us2.ai, a leading MedTech firm backed by prominent investors including IHH Healthcare, Heal Partners, Peak XV Partners (formerly Sequoia India) and EDBI announces FDA clearance for Us2.v2, featuring 45 automated echo parameters, including strain analysis [1], marking a significant stride in medical innovation. Us2.v2 is an advanced image post-processing…

Read More
AI to Diagnose RHD

AI for Rheumatic Heart Disease

By Us2.ai / 17 January, 2024 / Comments Off on AI for Rheumatic Heart Disease

Each year, RHD kills nearly 400,000 people globally. Experts at Children’s National Hospital deployed algorithms on the Us2.ai platform to detect early-stage RHD with the same accuracy as a cardiologist. “AI will tell you to move (the probe) left or right to get the ideal picture… Even more importantly, we’ve developed technology that can tell…

Read More